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A colostral proline-rich polypeptide complex (PRP) consisting of over 30 peptides shows beneﬁcial
effects in Alzheimer’s disease (AD) patients when administered in the form of sublinqual tablets
called Colostrinin. The aim of the present studies was to investigate whether nanopeptide fragment
of PRP (NP) – one of the PRP complex components can affect aggregation of amyloid b (Ab1-42). The
effect of NP on Ab aggregation was studied using Thioﬂavin T (ThT) binding, atomic force micros-
copy, and analyzing circular dichroism spectra. Results presented suggest that NP can directly inter-
act with amyloid beta, inhibit its aggregation and disrupt existing aggregates acting as a b sheet
breaker and reduce toxicity induced by aggregated forms of Ab.
 2008 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction cytokines [14,15]. PRP affects both, innate and adaptive immuneA proline-rich polypeptide complex (PRP) ﬁrst isolated from
ovine colostrum and subsequently found in human and cow colos-
tra is composed of a mixture of peptides of various molecular
masses ranging from 500–3000 kDa. PRP contains a high propor-
tion of proline residues and hydrophobic amino-acids 25% and
40%, respectively [1–4].
The PRP complex has shown immunoregulatory properties,
inducing the maturation and differentiation of murine thymocytes,
and affecting humoral and cellular immune responses, both
in vitro and in vivo. The polypeptide is not species-speciﬁc and is
active in mice, humans, chickens, and rats [2,5–9]. A nanopeptide
(NP) fragment of the PRP complex: Val-Glu-Ser-Tyr-Val-Pro-Leu-
Phe-Pro, both isolated from the chymotrypytic digestion products
and obtained by chemical synthesis shows in mice the full spec-
trum of immunotropic activities of the untreated ovine PRP
[10,11].
The PRP complex affects the differentiation/maturation process
of cells of monocyte/macrophage lineage [12] and shows regula-
tory effects on secretion of NO [13], reactive oxygen species, andchemical Societies. Published by E
lex from ovine colostrum; NP,
sease; Ab, amyloid b; ThT,
e microscopy
M. Janusz).responses and seems to restore balance in cellular immune
functions.
PRP and NP show beneﬁcial effects on the cognitive functions in
older rats [9,16] and PRP improve mood and cognitive abilities in
humans [8]. PRP, in the form of sublinqual tablets called Colostri-
nin, containing 100 lg of PRP, improves the outcome of Alzhei-
mer’s disease (AD) patients and prevents further deterioration of
the patients’ health status [17–19].
Deposits of amyloid b protein in neurite plaques and cerebral
vessels are a pathological hallmark of AD. Aggregates and ﬁbrilar
amyloid b (Ab) deposits are closely associated with inﬂammatory
responses, activation of microglia. Ab stimulates the glial overpro-
duction of interleukins, ROS, and NO [20–23]. One of attractive
therapeutic approaches to AD is use of preparations which may in-
hibit aggregation and formation of insoluble deposits of Ab in the
brain or preparations which may disrupt aggregates of Ab already
formed [24–26] and prevent its toxicity [27,28].
The mechanism of action of PRP in AD patients is not yet fully
clariﬁed. It was of interest to ﬁnd out whether PRP and its compo-
nent peptides, besides regulatory properties in inﬂammatory pro-
cesses, can affect formation of aggregates of Ab and thus reduce
the cytotoxic effects of the amyloid.
As the PRP complex is a mixture of over 30 peptides, in our
studies we used the nanopeptide NP, one of its components show-
ing similarity to PRP in regulation of immune and cognitivelsevier B.V. All rights reserved.
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using Thioﬂavin T (ThT) binding, atomic force microscopy, and ana-
lysing circular dichroism spectra (CD). The results obtained
showed that NP acts as a b-sheet breaker and may inhibit Ab aggre-
gation and disrupt existing aggregates.
2. Materials and methods
2.1. Aggregation of amyloid beta 1-42 (Ab1-42) and effect of NP
Ab1-42 was purchased from Bachem, Switzerland. NP: Val-Glu-
Ser-Tyr-Val-Pro-Leu-Phe-Pro was synthesized by a solid-phase
method and kindly provided by Professor G. Kupryszewski from
the Institute of Chemistry, University of Gdan´sk.
One milligrams samples of commercial preparations of Ab1-42
were dissolved in 1 ml of 1,1,1,3,3,3-hexaﬂuoro-2propanol (HFIP)
(Sigma, USA). If necessary, the samples were sonicated in ice-water
bath for 10 min. Aliquots containing 100 lg of Ab were dried in a
SpeedVac and stored at 80 C. For experiments, the dried samples
were dissolved in 300 ll of water (MiliQ) or PBS (ﬁnal concentra-
tion of Ab 74 lM) and incubated for various times at 37 C to induce
aggregation of Ab and formation of ﬁbrillar oligomeric species. To
measure the effect of NP, 100 lg samples of Ab were dissolved in
150 ll of water or PBS, mixed with 150 ll of solution of NP and
incubated at 37 C. The ﬁnal molar concentration of Ab was
74 lM and the proportion of NP to Ab was 5:1 or 1:1. At various
times, aliquots of Ab solutions without and with NP were with-
drown for examination using atomic force microscopy (AFM), CD,
and ThT binding. The concentrations of the nonaggregated, oligo-
meric, and ﬁbrilar Ab are based on the initial peptide mass.
2.2. Cell viability
Rat pheochromocytoma (PC12) cells were cultured in 75-cm2
ﬂasks at 37 C in 95% humidiﬁed atmosphere and 5% CO2 in Dulb-
eco’s modiﬁed Eagle’s medium (DMEM) supplemented with 10%
fetal bovine (Gibco, England) and 5% horse serum, 50 U/ml penicil-
lin/streptomycin, 2 mM L-glutamine (Sigma, USA). Viability of cells
incubated 72 h with Ab samples aggregated in the presence and in
the absence of NP was assessed by the trypan blue exclusion assay.
Cells (1  104) were treated with 0.4% trypan blue stain for 15 min.
Trypan blue excluding cells (live) and stained (dead) cells were
counted in a haemocytometer in three selected ﬁelds and aver-
aged. The number of dead cells was calculated as a percentage of
total number of counted cells.Fig. 1. In vitro ﬁbrillogenesis of Ab1-42 in the absence and in the presence of NP
followed by the ThT ﬂuorescence assay. Ab (74 lM) was incubated for 4 days at
37 C in the absence and in the presence of NP (370 lM). (A) Ab1-42 with a low and
(B) with a high 0 time ThT binding. Results shown are from a single representative
experiment (two similar experiments were performed in triplicate). The results are
presented as percentage vs ThT binding at 0 time assumed to be 100%.2.3. Atomic force microscopy (AFM)
Ab aggregation performed in the absence and in the presence of
NP in molar ratio 1:1 or 1:5 were imaged with modular atomic
force microscope. Five microliter samples of Ab (74 lM) incubated
for 6 days at 37 C in the absence and in the presence of NP (74 lM
or 370 lM) in 50 mM phosphate buffered saline was deposited on
freshly cleaved mica and dried in nitrogen. Maximal scanning area
was 20.5 lm  20.5 lm for samples of height below 2 lm. The sil-
icon cantilever with an integrated thermal actuator and piezoresis-
tive Wheatstone bridge detector was used as a nanoforce sensor
[29]. Cantilever resonance vibrations were achieved by periodically
dissipating power in the thin ﬁlm heater structure. Sine signal from
the piezoresistive bridge was ampliﬁed and converted to its true
RMS (root mean square) value using a selective electronics. The
surface topography measurements were taken using shear-force
mode, where the probe vibrated perpendicularly to the sample sur-
face. Constant distance between microtip and the sample was
maintained using an analog PID controller. Measurements of thesurface topography were performed in electroaccustically isolated
chamber at room temperature and ambient pressure with 50%
humidity. At least four regions of the mica surface were examined
to ensure that similar structures existed throughout the sample.
2.4. Thioﬂavin T (ThT) binding
The time-course of aggregation of Ab was monitored with ThT
(Sigma, USA), a ﬂuorofore that shifts excitation and emission max-
ima upon binding to amyloid ﬁbrils [30]. Twenty microliter of
74 lM Ab solution was added to 980 ll of ThT (5 lM ThT in
50 mM glycine–NaOH buffer, pH 8.5), and mixed in a Vortex. The
ﬂuorescence was read within 1–2 min in a Perkin–Elmer LS-50
spectroﬂuorimeter (kexc 440 nm, kem 485 nm). The ﬁnal concentra-
tion of Ab in the assay was 1.48 lM.
2.5. Circular dichroism (CD)
The samples were measured in 0.1 cm path-length cells at room
temperature with Jasco-600 spectropolarimeter equipped with a
computerized data processor. MiliQ water was used as a solvent.
Spectra were recorded at 1 nm intervals over the wavelength range
180–260 nm. Results are expressed in terms of molar elipticity (h)
in units of degree cm2 dmol1. All the spectra were obtained by
subtracting water base-line spectra and smoothed by using the
algorithm provided by Jasco. The peptide solutions: Ab (74 lM),
Ab + NP (74 lM + 370 lM), NP (370 lM), were analysed at various
time intervals over 6 days of incubation at 37 C. The samples for
CD measurements were diluted 4–8 fold to secure measurements
in the far UV range.
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3.1. Thioﬂavin T binding
ThT is a dye that increases its ﬂuorescence intensity upon bind-
ing the peptides with a beta-sheet conformation and is therefore
used to estimate the relative amount of beta-sheets in a sample
[30]. Therefore, to determine whether NP affects ﬁbrillogenesis
and amyloid formation, we measured ﬂuorescence emission of
ThT bound to amyloid ﬁbrils.
In our studies we used commercially available batches of the
amyloid peptide Ab1-42. Different commercially available batches
of Ab1-42 can have different starting aggregation states and struc-
ture which will then in turn affect their solubility, aggregation
rates, biological activities in solutions [31]. Nevertheless, all
batches incubated at 37 C for several days showed a signiﬁcantly
higher content of beta-sheeted ﬁbrils than the amyloid at 0 time.
To determine whether NP affects Ab ﬁbrillogenesis, we mea-
sured aggregation of Ab1-42 in the absence and in the presence
of NP. We compared two batches of Ab1-42, one with a low
(Fig. 1A) and one with a high (Fig. 1B) ﬂuoresecence at 0 time
of incubation. In both cases, NP inhibited the aggregation of Ab
by 34–52%. Moreover, NP disrupted aggregates of Ab present
from the beginning (0 time) in solutions of some commercial
preparations (Fig. 1B). During prolonged incubation (7 and more
days) formation of insoluble amyloid-like structures of Ab was
observed. The presence of NP inhibited the precipitation
(Fig. 1A and B). In control experiments, NP showed no binding
of ThT.Fig. 2. Comparison of circular dichroism spectra of Ab1-42 incubated in the absence an
indicated times at 37 C in the presence of NP were obtained after subtraction of base-l3.2. Circular dichroism (CD)
Solutions of nonaggregated Ab1-42 measured in water solu-
tions display CD spectra characteristic for random coil [32]. Incu-
bation of Ab samples at 37 C induces conformational changes of
Ab from random coil to beta-sheet structure, ﬁbril formation and
precipitation in an amyloid-like oligomeric beta-pleated sheet
structure [32–36]. During incubation, the elipticity for CD band
centered at 195 nm (max.) and 217 nm (min.) get stronger,
corresponding to an increase in the amount of soluble beta-sheet
structure [37].
CD spectra of our commercially obtained Ab1-42 solubilized in
water showed the presence of negative elipticity at 217 nm and
positive one at 195 nm characteristic for b-sheet conformation.
This indicated the presence of aggregates in our Ab preparations.
The changes observed during 1–6 days incubation at 37 C indi-
cated further transition of Ab into beta-sheet conformation. CD
spectra of water solutions of NP did not change during for 6 days
(not shown). Comparison of the CD spectrum for Ab + NP with
the sum of CD spectra of Ab and NP indicated that NP can directly
interact with Ab.
To study the effect of NP on the aggregation of Ab1-42, transition
into b-structure, we measured the CD spectra of water solutions of
Ab, Ab + NP, and NP incubated at 37 C for various time intervals.
As our commercial preparations of Ab1-42 contained, ab initio,
aggregates of Ab, we decided to compare spectra of Ab incubated in
the absence of NP with the spectra of Ab incubated in the presence
of NP – difference spectra obtained by subtraction of buffer base-
line spectra including NP. The effect of NP on the content of b-sheetd in the presence of NP (Ab in the mixture). Spectral tracings for Ab incubated for
ine and NP elipticities from the Ab + NP values (molar ratio Ab:NP 1:5).
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is shown, NP caused an immediate reduction in the amount of b-
sheet structure at time 0 and inhibited further transition of Ab into
b-sheet conformation during 6 days incubation. The results ob-
tained showed that NP directly interacted with Ab and may disas-
sembly aggregates of Ab and inhibit progressive aggregation and
formation of b-sheet structure.3.3. Atomic force microscopy (AFM)
Atomic force microscopy (AFM) provides quantitative and high
resolution three dimensional morphological information which
can hardly be obtained using other techniques. In our experiments
we used 74 lM solutions of Ab1-42 in 0.5 mM phosphate buffer,
pH 7.0, incubated for 6 days at 37 C in the absence and in the pres-
ence of NP (molar ratio NP:Ab = 1:1 or 5:1).Fig. 3. AFM images of Ab aggregates formed in the absence and in the presence of NP. Ab1
NP. Ex situ images of samples deposited on mica are presented as three dimensional im
side – in the absence of NP; right side – in the presence of NP.In the case of commercial preparations of Abwith a low content
of aggregates and in the case of NP no presence of any speciﬁc
structures was observed in AFM images at 0-time of incubation.
However, 6 days incubation of Ab induced formation of aggregates.
Three-dimensional AFM image (Fig. 3) indicates the presence of
coalescent aggregates of various extent of branching with the
height of 34 nm. The aggregates exhibited a wide variety of shapes.
In the two-dimensional images folded bands of aggregated Ab
which might represent the aggregated ﬁbrils of Ab and globular
structures are visible. The amyloid nature of the aggregates was
indicated by ThT binding and b-sheet-rich far ultraviolet CD. On
the other hand, AFM images of Ab incubated for 6 days in the pres-
ence of NP (molar ratio Ab:NP = 1:1) showed only small spheroidal
or ellipsoidal structures of height not exceeding 9 nm (Fig. 3). Solu-
tions of NP showed after 6 days of incubation the presence of only
a few small unstructured aggregates wit a height about 1 nm (data
not shown).-42 (74 lM) was incubated for 6 days at 37 C in the absence and in the presence of
age (A) two-dimensional image (B) and cross-section of AFM height image (C). Left
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tio, aggregated forms, showed at time 0 the presence of aggregates
which further strongly aggregated within 6 days of incubation
forming linear bands structures which further change into three-
dimensional super aggregates with a height of 79 nm. However,
when Ab was incubated with NP (molar ratio Ab:NP = 1:1) three-
dimensional AFM image showed the presence of shortened linear,
branched aggregates (not shown). The inhibitory effect of NP on Ab
aggregation was even more visible when the concentration of NP
was enhanced (molar ratio Ab:NP = 1:5). AFM image (Fig. 4)
showed only the presence of small amorphous structures of height
of 19 nm. Every sample surface was examined several times in
different places using the scanning area of a few microns.
Representative set of data, where we obtained average results,
was shown in Figs. 3 and 4.
The results obtained showed that NP not only inhibited forma-
tion of large aggregates of Ab but also induced deaggregation of Ab
aggregates already present.Fig. 4. Effect of the NP on deaggregation of the Ab1-42 aggregates (AFM). Ab1-42 (74 lM
the absence and in the presence of NP in a molar ratio 1:5. (A) Three-dimensional image,
the absence of NP; right side – in the presence of NP.3.4. Cell viability
Cell viability was measured by trypan blue exclusion assay. The
results are presented as percentage of cells mortality in the pres-
ence of Ab aggregated with or without of NP. As is shown in
Fig. 5, in the presence of NP, both added to the cell simultaneously
with bA or 24 hours before, toxic effect of Ab is reduced up to about
1=4 of the value obtained in the absence of NP. No toxic effect of NP
was observed. The results obtained show that the reduction of Ab
peptides aggregation by NP is concomitant with the reduction of
the cytotoxic effects of b-amyloid on PC-12 cells.
4. Discussion
One of a hallmark’s of AD is the accumulation of depositions
of insoluble amyloid ﬁbrils as senile plaques in the brains of
patients. Fibrillation proceeds via amyloid structures ranging from
oligomers to protoﬁbrils and ﬁbrils. Transient, large globular or) preparation containing ab initio aggregated forms of Abwas incubated for 6 days in
(B) two-dimensional image, and (C) cross-section of the height image. Left side – in
Fig. 5. Effect of NP of PC-12 cell viability. Cells were incubated for 72 h in the
absence or in the presence of Ab1-42 (1 lM), NP (1 lM), Ab + NP (molar ratio 1:1) or
pretreated with NP for 24 h and then treated with Ab. The results presented are the
means value of three independent experiments performed in triplicates. *Statisti-
cally signiﬁcant differences versus amyloid b, P 6 0.05.
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ques predominantly consist of aggregates of Ab peptides [22].
Aggregated Ab have been demonstrated to adopt a primarily b-
sheet conformation in solution [22,33]. Soluble b-sheet structure
is a precursor to the insoluble b-pleated sheet structure in amyloid
plaques and is neurotoxic to neuronal cells [20,22,35]. As Ab aggre-
gates impair neuronal viability and function, drugs that inhibit the
aggregation process may serve as effective therapeutics [38,39].
Tjernberg et al. [40] found that Ab recognition element KLVFF
(residues 16–20 of Ab) interacts with full length Ab and inhibits ﬁ-
bril formation. Subsequently, it was found that short synthetic
peptides capable of binding Ab, but not unable to become part of
a b-sheet structure (b-sheet breaker peptides) may destabilize
the amyloidogenic Ab conformer and hence preclude amyloid for-
mation [41–45].
It was of great interest to investigate whether the colostral pro-
line-rich polypeptide complex which in form of sublinqually
administered tablets, Colostrinin, shows positive effects in the case
of AD, is able to affect the aggregation of Ab. Recently, Schuster
et al. [46] in experiments on aggregation of Ab1-40 showed results
suggesting that PRP/Colostrinin is a b-sheet breaker with an ability
to prevent aggregation of Ab1-40 and disrupt existing aggregates.
The aim of our studies was to investigate whether a NP, a com-
ponent of PRP with known structure, immunotropic and procogni-
tive properties [10,11,16], can affect the aggregation of Ab1-42.
Despite the small structural difference between Ab1-40 and
Ab1-42, they display distinct clinical and biological behavior.
Ab1-42 displays enhanced neurotoxicity relative to Ab1-40 and it
forms aggregates and ﬁbrils signiﬁcantly faster than Ab1-40.
Amyloid peptide Ab1-42 is the predominant component in paren-
chymal plaques [47,48].
Measurements of ThT binding, circular dichroism spectra, and
atomic force microscopy indicated that NP was able to inhibit
aggregation and b-sheet structure formation of Ab1-42 in vitro. It
also was shown that NP disassembled aggregates of Ab already
present in solutions of commercial Ab1-42 preparations. Studies
of CD spectra indicated that NP directly interacted with Ab and acts
as a b-sheet breaker. NP molecule possesses all properties expected
from b-sheet breakers. It contains hydrophilic and hydrophobic
segments and proline residues, as was described in the case of other
b-sheet breakers [41,42,49]. The presence of Pro residues as b-sheet
blocker residues is important for conformational ﬂexibility and for
destabilizing intermolecular b-sheets of Ab aggregates [41,50].
There always is a problem how the results obtained from model
system are related to process in vivo. In the case of PRP/Colostrinin,
it is difﬁcult to follow its pathways in the organism. The tablets ofPRP/Colostrinin contain 100 lg of the PRP complex composed of
more than 30 peptides. So the mechanism of action of PRP/Colostr-
inin can be deduced from the studies on model systems. PRP/
Colostrinin was applicated to the AD patients in the form of sublin-
qual tablets. Oral-mucosal rout offers excellent accessibility, avoids
degradation of protein and peptides that occurs as a result of oral
administration, gastrointestinal absorption, and ﬁrst-pass hepatic
metabolism [51]. Peptides penetrating into the mucous membrane
may gain access to the systemic circulation via a network of capil-
laries and arteries. It was shown, in various laboratories, that pep-
tides can pass the blood–brain barrier using saturable transport
systems (blood–brain, brain–blood), passive diffusion from blood
to brain or saturable transport system after activation [52–54].
At present, we have no experimental evidence that PRP/Colostr-
inin can pass the blood–brain barrier. Neverthless, we can hypoth-
esize that the PRP/Colostrinin might affect formation of the
aggregates of the amyloid b peptides. Schuster et al. [46] showed
that PRP/Colostrinin, even at low concentrations (2.5 nM
and below) can affect the aggregation of Ab and inhibit its
aggregation.
It is assumed that aggregated forms of Ab are responsible for the
neurotoxic effects of this peptide [55]. Our results showed that one
of components of the PRP/Colostrinin, the NP, can directly interact
with Ab and inhibit its aggregation. We can assume that PRP pep-
tides, including NP, might cross the blood–brain barrier, enter the
brain and interact with Ab. Another possibility is that the PRP pep-
tides might react with Ab present in the serum affecting the ex-
change of Ab between the blood and the brain and inhibiting the
formation of Ab aggregates. The second possibility was used as
an explanation of the mechanism of action of anti-Ab antibodies
applicated to the AD patients [56].
The results presented in this paper suggest that PRP/Colostrti-
nin provides not only a combination of antioxidative and immuno-
regulatory effects which can all be important for the therapeutic
effects of Colostrinin in AD patients, but also show that NP, the
peptide component of PRP with the known primary structure
and immunoregulatory and procognitive activities, can directly
interact with Ab and prevent formation of cytotoxic aggregates.
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